Ibrutinib becomes first approved treatment for rare B-cell lymphoma

Further information
View Imbruvica drug record 
Summary of Product Characteristics
Manufacturer: Janssen Cilag

The Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has been approved for the treatment of patients with Waldenström's macroglobulinaemia.

Imbruvica is indicated in patients with the rare non-Hodgkin's lymphoma who have received at least one prior therapy for the condition, or as first-line treatment for patients unsuitable for chemo-immunotherapy.

Imbruvica was previously licensed only for the treatment of relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more